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Abstract
Background and Objectives
Describe the unique functions of immunoglobulin G4 (IgG4) in IgG4-neurologic disorders
(IgG4-ND) and explain why, in contrast to their IgG1-counterparts, they respond poorly to
intravenous immune globulin (IVIg) but eﬀectively to anti–B cell therapies.
Methods
The IgG4 structure and isotype switch, B cells and plasmablasts relevant to IgG4 production,
and IgG4-induced disruption of the targeted antigens are reviewed and compared with IgG1mediated autoimmune ND, where IVIg inhibits IgG1-triggered inﬂammatory eﬀects.
Results
The main IgG4-ND include muscle-speciﬁc kinase myasthenia; nodal/paranodal chronic inﬂammatory demyelinating polyradiculoneuropathy with antibodies to neurofascin-155, contactin-1/
caspr-1, or pan-neurofascins; antileucine-rich, glioma-inactivated-1 and contactin-associated proteinlike 2 associated-limbic encephalitis, Morvan syndrome, or neuromyotonia; and anti-IgLON5 disorder. The IgG4, because of its unique structural features in the hinge region, has noninﬂammatory
properties being functionally monovalent and bispeciﬁc, unable to engage in cross-linking and internalization of the targeted antigen. In contrast to IgG1 subclass which is bivalent and monospeciﬁc,
IgG4 does not activate complement and cannot bind to inhibitory Fcγ receptor (FcγRIIb) to activate
cellular and complement-mediated immune responses, the key functions inhibited by IVIg. Because
IVIg contains only 0.7%–2.6% IgG4, its idiotypes are of IgG1 subclass and cannot eﬀectively neutralize
IgG4 or suﬃciently enhance IgG4 catabolism by saturating FcRn. In contrast, rituximab, by targeting
memory B cells and IgG4-producing CD20-positive short-lived plasma cells, induces long-lasting
clinical beneﬁts.
Discussion
Rituximab is the preferred treatment in IgG4-ND patients with severe disease by eﬀectively
targeting the production of pathogenic IgG-4 antibodies. In contrast, IVIG is ineﬀective because
it inhibits immunoinﬂammatory functions irrelevant to the mechanistic eﬀects of IgG4 and
contains IgG-1 idiotypes that cannot suﬃciently neutralize or possibly catabolize IgG4. Controlled studies with anti-CD19/20 monoclonals that also activate FcγRIIb may be more
promising in treating IgG4-ND.
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Glossary
AChR = acetylcholine receptor; CASPR2 = contactin-associated protein-like 2; CIDP = chronic inﬂammatory demyelinating
polyradiculoneuropathy; CTL = cytotoxic T lymphocytes; FcγR = Fcγ receptor; IgG4 = immunoglobulin G4; IgG4-ND =
IgG4-neurologic disorder; IgG4-RD = IgG4-related disease; IVIG = intravenous immune globulin; LGI1 = leucine-rich,
glioma-inactivated-1; MAC = membranolytic attack complex; MG = myasthenia gravis; MuSK = muscle-speciﬁc kinase; PNS =
peripheral nervous system.

Several autoimmune, multisystemic, or ﬁbroinﬂammatory disorders have been recently identiﬁed based on their association
with immunoglobulin G4 (IgG4) subclass of autoantibodies,
referred to as IgG4-related diseases (IgG4-RD).1-3 In contrast,
however, to a broad IgG4-RD spectrum with nondiseasespeciﬁc pathogenic autoantibodies except for pemphigus
vulgaris, membranous nephropathy, and thrombotic thrombocytopenic purpura, we are witnessing key IgG4-neurologic
disorders (IgG4-ND) with pathogenic IgG4 antibodies targeting neural antigens highlighted by MuSK-myasthenia;
nodal/paranodal chronic inﬂammatory demyelinating polyradiculoneuropathy (CIDP) with paranodal antibodies to
neurofascin-155, contactin-1, contactin-associated protein-like
1 (CASPR1), and nodal/paranodal pan-neurofascins (NF140/
NF186/NF155); leucine-rich, glioma-inactivated-1 (LGI1) or
the juxtaparanodal CASPR2-associated autoimmune encephalitis, Morvan syndrome, neuromyotonia, or autoimmune pain
syndromes; and the rare anti-IgLON5 disorder.4-10 The unique
feature of IgG4-ND is their signiﬁcant disease severity that, in
contrast to their IgG1 counterparts, exhibit poor response to
intravenous immune globulin (IVIg) and inadequate response
to steroids or plasmapheresis but excellent response to anti–B
cell therapies, such as rituximab, that downregulate humoral
immunity. Although some of these patients may have unique
clinical phenotypes, most often present similarly to IgG1
counterparts and treated identically until recognized in retrospect that they are refractory to conventional immunotherapies. Their resistance to these therapies especially IVIg, which
is the treatment of choice in their IgG1-counterparts based on
controlled trials, is poorly understood, leading to therapeutic
delays necessitating vigilance for proper therapy initiation.
Because IgG4-ND are now increasingly recognized, it has become
imperative to understand the uniqueness of IgG4 pathogenicity
and the rationale of the most eﬀective immunotherapies. For the
neurologists, the information is also relevant to IgG4-RD which,
although present with autoimmune multisystemic, lymphoproliferative, or ﬁbroinﬂammatory conditions, may also exhibit neurologic manifestations of meningeal and spinal cord disease,
hypertrophic pachymeningitis, orbital myositis, or hypophysitis
that may also need neurologic expertise.
The article addresses the uniqueness of IgG4 isotype; the role of
regulatory B cells, cytokines, and plasmablasts in the IgG4 production; the mechanism by which IgG4 antibodies cause dysfunction of their targeted antigens; the reasoning of why IVIg,
which is often the ﬁrst-line therapy in their IgG1 counterparts, is
2

ineﬀective; the currently successful anti–B cell therapy with rituximab, including practical issues on repeated infusions or IgG4
biomarkers; and promising future anti-IgG4-immunotherapies.
The Uniqueness of IgG4 Antibodies
IgG4 antibodies evolve as an anti-inﬂammatory response to
chronic antigenic stimulation traditionally connected to peripheral tolerance because of high-dose allergen exposure, as
occuring in beekeepers, cat owners, or helminth-infected
subjects, alleviating allergic inﬂammation by interfering with
the binding of allergen-speciﬁc IgE to the allergens.2 In
healthy adults, IgG4 is the least common IgG subclass,
comprising only 5% of the total IgG with a concentration of
0.08–1.4 g/L.1-3 Owing to its unique structural features in the
hinge region, the IgG4 antibodies, although continuously
undergo half antibody exchange with other IgG4 molecules,
are considered immunologically inert and functionally
monovalent because, in contrast to IgG1 which are bivalent
and monospeciﬁc, they recognize the antigen essentially with
only 1 Fab-arm of the IgG4; as a result, they are unable to
engage in cross-linking and internalization of their target antigen or form immune complexes having noninﬂammatory
properties.1,3,5,11 IgG4 functions diﬀerently from the other
IgG subclasses by 2 key characteristics: ﬁrst, cannot bind the
ﬁrst C1q complement component to activate the complement
cascade, and second, they bind uniquely to Fc receptors with
markedly reduced binding capacity to inhibitory Fcγ receptor
(FcγRIIb) but with enhanced binding to the activating
FcγRI.1-3 Collectively, IgG4-antibodies are inadequate in activating cellular or complement-mediated immune responses,
which are directly targeted by IVIg and conventional immunotherapies; instead, they exert their pathogenicity by
blocking protein-protein interactions and aﬀecting signal
transduction pathways. Whether genetic factors promote the
development of IgG4 isotype as a response to certain antigens, as noted for certain paranodal antibodies mentioned
later, is a possibility that needs to be further explored.
Role of Cytokines, T Cells, and B Cells in IgG4
Production and Isotype Switch
The IgG4 production is augmented by IL-10, which in IgG4RD is overexpressed in aﬀected tissues playing a key role in
the isotype switching of B cells to IgG4 subclass.1-3 IL-10expressing T-follicular regulatory cells and follicular helper T
(Tfh) cells that produce IL-4, IL-10, and IL-21 are also involved in class switch, contributing to the pathogenesis of
IgG4-RD.1,3,11-14 CD4+ cytotoxic T lymphocytes (CTLs) are
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prominent in IgG4-RD and decline after B cell-targeted
therapy, suggesting that B cells present antigen to activate
CD4+ CTLs.1 Memory B cells and plasmablasts are also increased in the peripheral blood with the expansion of IgG4producing CD19ﬂCD20+CD27hiCD38hi plasmablasts, especially during relapses or active disease.1-3

2.

Insidious isotype switch can also occur late in the immune response
because of maturation and hypermutation, as noted in nodal
CIDP, from IgG3 against CNTN1/CASPR1 to IgG4 against
CASPR115 and in MuSK-MG from IgG4 to IgG1.5 Although
overlooked, isotype switch can be clinically important in IgG4-ND
when patients previously responding to IVIg become IVIgunresponsive after isotyped to IgG4.
IgG4-Neurologic Autoimmunity: The Effect of
IgG4 Antibodies on Targeted Antigens
The IgG4 antibodies arise after chronic antigenic exposure
late in the immune response and exhibit very high aﬃnity for
their antigen after undergoing several rounds of aﬃnity
maturation and somatic hypermutation.16 In contrast to
most IgG4-RD, however, where the immunopathogenicity
of IgG4 is poorly understood and their clinicopathology is
broad—deﬁned by increased serum IgG4 and tumefactive
lesions with IgG4+ plasma cell inﬁltrates in multiple
organs1,2—the IgG4-neuroautoimmunity is distinct, characterized by antigen-speciﬁc disorders aﬀecting only CNS or
PNS. Most importantly, in IgG4-ND, the IgG4 antibodies
exert a direct pathogenic eﬀect by blocking enzymatic activity or disrupting protein-protein interactions of their
target antigens aﬀecting signal transduction pathways.5
Among the IgG4-RD, the main ones with antigen-speciﬁc
IgG4 that share immunologic similarities with IgG4-ND are
pemphigus vulgaris with antidesmoglein antibodies, membranous nephropathy with M-type phospholipase A2 receptor 1 or thrombospondin type-1 antibodies, thrombotic
thrombocytopenic purpura with antibodies to metalloprotease ADAMTS13, and possibly Goodpasture syndrome with antitype IV collagen antibodies. The IgG4-ND
include
1.

Anti-MuSK-MG. It comprises 7% of all patients with
myasthenia gravis (MG) and is highlighted by IgG4
antibodies against muscle-speciﬁc kinase (MuSK), a
transmembrane polypeptide expressed at the neuromuscular junction, that plays a fundamental role in
acetylcholine receptor (AChR) clustering via interactions
with agrin and rapsyn.4,5 Although MuSK-MG may have
a phenotype similar to AChR-MG, many times has
unique presentation with selective weakness and atrophy
of the neck, tongue, shoulder, and bulbar muscles.17,18
MuSK-IgG4 antibodies are pathogenic, can passively
transfer disease, and cause dysfunction of the neuromuscular junction by interfering with AChR clustering
through the inhibition of Lrp4/MuSK signaling, but
not by antigen cross-linking, internalization, or end-plate
destruction as the IgG1-AChR antibodies do.4,19
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CIDP with nodal/paranodal antibodies. This clinicopathologically distinct CIDP subset, identiﬁed in the last
10 years, comprises 10% of patients with CIDP and is
caused by IgG4 antibodies to paranodal neurofascin-155,
CASPR1, and CNTN16,20-22 and the nodal/paranodal
pan-neurofascin (NF140/NF186/NF155 also called
“nodal neurofascin”). These patients have distinct
clinical phenotypes with distal weakness, tremor, and
sensory (proprioceptive) ataxia. NF155 is a Schwann
cell adhesion protein at the paranodal terminal myelin
loops that binds to CNTN1, forming a complex critical
for the maintenance of nodal structures ensuring rapid
impulse propagation.23 The antibodies are pathogenic,
disrupting the NF155/CNTN1 complex by binding
distinct epitopes associated with cell adhesion, resulting
in the disadhesion of NF155/CNTN1 components by
aﬀecting glycosylation.6,20,22,23 The IgG4 NF155 antibodies are speciﬁcally deposited at the axoglial junction
causing dissection at the paranode perturbing conduction
in the absence of demyelination.23,24 These antibodies do
not ﬁx complement or internalize target antigens and do
not cause inﬂammation; instead, they block proteinprotein interaction leading to conduction failure.5,23
Speciﬁc HLA-DRB1*15 alleles show strong association
in anti-NF155 patients implicating a constitutive genetic
risk susceptibility factor.25
LGI-1 and CASPR2-autoimmune syndromes presenting
with limbic encephalitis and seizures, Morvan syndrome
and neuromyotonia, or severe neuropathic pain. These
IgG4 antibodies are directed against the leucine-rich,
glioma-inactivated-1 (LGI1) antigen or the juxtaparanodal
contactin-associated protein-like 2 (CASPR2) that stabilize
the voltage-gated potassium channel complex into the
membrane.7-9 The LGI1 plays a role in bridging the
presynaptic voltage-gated potassium channel protein Kv1.1
with the postsynaptic a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor through interaction with
synaptic anchor molecules ADAM22/23; the anti-LGI1
antibodies alter the binding of LGI1 with ADAM22,
decreasing the postsynaptic levels of a-amino-3-hydroxy-5methyl-4-isoxazolepropionic acid receptors.8
Although patients with anti-LGI-1 and CASPR2 antibodies may exhibit overlapping clinical symptomatology,
the antibodies to LGI1 are most commonly associated
with limbic encephalitis and epilepsy, whereas antibodies
to CASPR2 with Morvan syndrome and neuromyotonia.
Refractory epilepsy and mental and behavioral abnormalities are variably present. Pain, as seen in small ﬁber
sensory neuropathy, and seizures involving ipsilateral face
and limb dystonia-like seizures are also increasingly
recognized.

4. Anti-IgLON5 disorder deﬁnes a complex syndrome of
gait instability, craniofacial dyskinesias, sleep-disordered
breathing, abnormal eye movements, and cognitive
decline, characterized by antibodies, mostly of IgG4
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Figure Immunopathogenic Network in IgG1-ND as Related to the Actions of IVIg (*1–5), Highlighting (*1–5 X) the Effects
Irrelevant to IgG4-ND

In IgG1-ND, antigens presented via antigen presenting cells to CD4+T cells stimulate B cells to produce IgG1 antibodies which, by fixing complement at the
target organ, lead to tissue damage. FcRn plays a role in catabolism of IgG1 antibodies, whereas the inhibitory FcγRIIB receptors on macrophages and B cells
mediate inflammatory and immune effector functions. Induction of Tregs and proinflammatory cytokines sustain immune imbalance (adapted from 58). IVIg
is effective in IgG1-ND collectively by supplying idiotypic antibodies of IgG1 subclass that exert neutralizing effects on circulating pathogenic IgG1 autoantibodies (*1); this function is irrelevant to IgG4-ND because IVIg contains only IgG1 isotypes that cannot neutralize IgG4 (*1-X); saturating the FcRn in
endosomes resulting in increased catabolism of pathogenic IgG1(*2); this function is probably irrelevant to IgG4-ND because IgG1 isotypes may not
sufficiently affect IgG4 catabolism (*2-X); binding to C3b, intercepting complement activation and the destructive effects of complement-fixing IgG1 antibodies (3*); this function is irrelevant to IgG4-ND because IgG4 does not fix complement (3*-X); upregulating FcγRIIB receptors on macrophages and B cells
(*4); this function is irrelevant to IgG4-ND because IgG4 cannot bind to FcγRIIB (*4-X); and inhibiting proinflammatory cytokines (5*); this is irrelevant to IgG4ND because IgG4 has anti-inflammatory effects and does not sufficiently induce such cytokines (*5-X). IgG1-ND = IgG1-neurologic disorder; FcγRIIb = Fcγ
receptor; IVIg = intravenous immune globulin.

isotype, against IgLON5, a neural cell adhesion
molecule.10 IgLON5 antibodies disrupt the crosstalk
between cell surface and cytoskeleton, leading to the
abnormal accumulation of neuroﬁlaments, providing a
link between antibody-mediated autoimmunity and
neurodegeneration.26
Why IVIg Is Ineffective in IgG4-ND: Mechanisms
of Actions of IVIg in Relevance to
IgG4 Antibodies
In contrast to their autoimmune-ND counterparts that respond to IVIg in controlled studies, in IgG4-ND, there is no
antigen cross-linking or immune complex formation, no recruitment of immune cells via Fc receptors, and no antigenic
destruction via phagocytosis or antibody-dependent cellular
cytotoxicity. Because these are the key functions inhibited by
IVIg,27,28 all the hallmark anti-inﬂammatory eﬀects of IVIg
that deﬁne its success in IgG1-ND are irrelevant to the
pathogenicity of IgG4, explaining not only the ineﬀectiveness
of IVIg but also the suboptimal beneﬁt of steroids. The key
4

immunoregulatory actions of IVIg, contrasting with their irrelevance in IgG4-ND, include (Figure)
1.

Supply idiotypic antibodies of IgG1 isotype capable of
neutralizing pathogenic autoantibodies via F(αβ’)2
binding. IVIg has more than 95% IgG of IgG1 subclass
but minimal IgG4 (0.7%–2.6%). Derived from thousands
of donors, IVIg contains anti-idiotypic IgG1 antibodies
with a wide range of idiotypic and anti-idiotypic
speciﬁcities, forming dimers connected by double-arm
or single-arm binding between their F(αβ’)2 domains that
bind to and neutralize pathogenic autoantibodies.27,29,30
The eﬀect of idiotypes within the IVIg is highlighted in
GBS and other demyelinating neuropathies with serum
anti-GM1, anti-GQ1b, or other anti-glycolipid antibodies
that block quantal release and impair neuromuscular
transmission; the IgG1-idiotypic antibodies within the
IVIg recognize these IgG glycoconjugates and inhibit or
neutralize the blocking eﬀects exerted by their sera,
explaining the quick clinical beneﬁts of IVIg.31,32 Because
IVIg does not contain idiotypes of IgG4 subclass, it
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2.

3.

4.

5.

cannot exert similar and suﬃciently enough neutralizing
or blocking eﬀects on the circulating IgG4 antibodies (#1,
Figure).
Acceleration of IgG1 catabolism by saturating the FcRn
transport receptors. Normally, IgG antibodies bind to FcRn
to return via endocytotic vesicles intact back into the
circulation, being protected from degradation by the
lysosomes.33 The supraphysiological levels of IgG derived
from IVIg administration saturate the FcRn, so a portion of
endogenously produced pathogenic IgG antibodies are not
recycled back to the circulation but degraded33,34; as a
result, the infused IVIg, by competing with pathogenic
autoantibodies for FcRn binding, reduces the serum half-life
of autoantibodies by approximately 40%, causing a
reduction of the circulating IgG.33-35 This eﬀect, although
not studied, may not be applicable to IgG4 antibodies
because IVIg has no IgG4 to aﬀect suﬃciently enough IgG4
recycling, adding to its ineﬀectiveness (#2, Figure).
Inhibition of complement binding and prevention of
membranolytic attack complex (MAC) formation. IVIg
inhibits complement uptake, intercepting the formation and
deposition of MAC on the targeted tissues by activated
complement or complement-ﬁxing antibodies.36,37 On this
basis, IVIg intercepts complement deposits on muscle or
nerve ﬁbers36-38 and prevents the cytotoxicity induced by
dermatomyositis or GBS sera.37,38 These key anticomplement eﬀects are not applicable to IgG4 antibodies because
they do not mobilize or ﬁx complement, as described earlier
(#3, Figure).
Modulation of FcγR. The FcγRs transduce either activating
signaling via the FcγRIA, FcγRIIA, and FcγRIIIA or
inhibitory signals via the FcγRIIB, regulating immune cell
activation.39,40 IgG molecules bind through their Fc region
to FcγR present on monocytes, macrophages, dendritic
cells, and B cells and mediate inﬂammatory or immune
eﬀector functions by activating or inhibiting intracellular
signaling, cellular activation, proliferation, and cytokine
production.27,39,40 IVIg selectively upregulates the inhibitory FcγRIIB, a negative regulator of lymphoid cell
activation, inhibiting phagocytosis and cytokine production
and intercepting antibody-dependent cell-mediated
cytotoxicity.39-41 Patients with CIDP have lower than
normal FcγRIIB expression on naı̈ve B cells and monocytes
but, after IVIG, the FcγRIIB expression is upregulated,
coinciding with clinical improvement.27,39,41,42 This important eﬀect, that also predicts response to IVIG in CIDP,39 is
not applicable to IgG4-ND because IgG4 antibodies cannot
bind to inhibitory FcγRIIB receptor, as mentioned earlier
(#4, Figure).
Suppression of pathogenic cytokines and immunoinﬂammatory molecules. IVIg eﬀectively suppresses proinﬂammatory cytokines,27,28,41 but such cytokines are
irrelevant in IgG4-ND because of the overall antiinﬂammatory eﬀects of IgG4 that cannot recruit immune
cells via Fc receptors or induce phagocytosis and trigger
tissue inﬂammation (#5, Figure).
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Rituximab Is the Preferred Treatment
in IgG-4-ND
The expansion of activated B cells that correlate strongly with
disease activity, the evidence of a pathogenic role for selfreactive B cells, and the clinical eﬃcacy of B cell-depletion
therapies1-3 strongly support rituximab as the treatment of
choice. Rituximab, a chimeric monoclonal antibody against
CD20, a 297 AA membrane-associated phosphoprotein present on all B cells, except stem cells, pro-B cells, and plasma
cells, depletes circulating B cells but not bone marrow and
lymph node B cells.43 Immunoglobulins are produced by
long-lived plasma cells, but IgG4 are likely produced by
CD20-positive short-lived plasma cells under the inﬂuence of
IL-4 and IL-21.44 Rituximab eliminates B cells before they
diﬀerentiate into plasma cells having no eﬀect on non-CD20expressing plasma cells; it reduces, however, IgG4 levels by
targeting IgG4-producing CD20-positive short-lived plasma
cells and their related CD20+ precursors, resulting in steep
decline of plasmablast counts.45 In several nonrandomized
trials in IgG4-RD, rituximab rapidly reduced serum IgG4
levels compared with serum IgG1.1-3
In IgG4-ND, the success of rituximab is also impressive. In
MuSK-MG, in a multicenter, blinded, prospective review,
58% (14/24) rituximab-receiving patients reached the primary outcome compared with 16% (5/31) of controls (p =
0.002), after a median follow-up of 3.5 years; furthernore, 29%
of rituximab-treated patients required a mean-prednisone
dose of 4.5 mg/d compared with 13 mg/d required by 74% of
controls (p = 0.005).46 IgG4-MuSK antibodies were markedly
reduced 2–7 months after rituximab, being even undetectable
within 2 years coinciding with clinical remission and sustained
improvement for several years47,48; in 1 patient who did not
respond, MuSK-IgG4 antibodies remained unchanged, supporting the view that short-lived antibody-secreting CD20+cells are the main producers of MuSK antibodies.47
In neurofascin-155 and CASPR1/CNTN1 CIDP, the evidence of IVIg unresponsiveness is overwhelming with less
than 10% partially and transiently responding to IVIg but
more than 80% responding to rituximab, as conﬁrmed in a
recent large patient collection.25 Similar is the experience in
LGI1 and CASPR2-associated encephalitis, where in a large
series the patients with worse outcome were those more
frequently treated with both IVIg and steroids; however, the
noted increased LGI1-speciﬁc plasmablasts/plasma cells in
these patients’ CSF fully justiﬁes anti-CD19-speciﬁc
immunotherapies.49
Rituximab Maintenance

In IgG4-RD, the risk of relapse tended to be lower with rituximab maintenance, compared with 1 rituximab induction
therapy with elevated serum IgG4 considered a risk factor for
relapse.1,3,50 The value of circulating IgG4 as a biomarker in
IgG4-RD is however unclear because IgG4 alone can nonspeciﬁcally increase in chronic immune activation.1 The IgG4
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levels also seem irrelevant in IgG4-ND; in 39 patients with
CIDP, including several with IgG4-nodal antibodies, the IgG4
concentration was normal (<1,350 mg/L, the limit for active
IgG4-RD [Dalakas et al. unpublished observations]). In
contrast, IgG4-ND antibody-speciﬁc titers seem to correlate
with disease activity as shown in MuSK-MG47 but also in
LGI1-encephalitis, where high CSF IgG4 titers strongly correlate with worse outcome.49 The need for follow-up rituximab infusions remains still empirical. Some prefer a repeated
infusion when clinical relapse occurs; others use 2 g every 6
months or 1 g every 3 months to ensure stability.43,47,48,51 The
most promising marker remains the re-emergence of CD27 +
memory B cells43,52,53; in 1 study, no MG relapses occurred
when the CD27 + memory B cells were below the therapeutic
target, whereas their resurgence was associated with clinical
relapses.52 Because reduction of IgG4-MuSK antibodies coincides with clinical remission,47 the value of follow-up antibody titers as a disease activity biomarker needs to be assessed
in all IgG-4 ND, as discussed below, along with the reappearance of memory B cells and IgG4-producing CD20positive short-lived plasma cells.
Future Therapies in IgG4-ND
Some of the novel therapeutic approaches targeting B cells or
CD4+ CTLs, currently evaluated in IgG4-RD, are also applicable to IgG4-ND and include (1) anti-CD19/20 including
rituximab, inebilizumab—now approved for NMO-SD54—
and obexelimab (XmAb5871) all in phase-3 trials in IgG4-RD.
Obexelimab, targeting CD19/FcγRIIB, is especially promising because it binds simultaneously to CD19 and FcγRIIb,
promoting internalization of CD19 in the lipid rafts55; obexelimab markedly enhances the inhibitory FcγRIIB and
downregulates CD19, both eﬀects tailored to IgG-4-ND by
also activating FcγRIIB receptor; (2) dupilumab against IL4Ra; (3) zanubrutinib and rilzabrutinib, both oral and
well tolerated Bruton’s tyrosine kinase inhibitors, now in
phase 2 trials in pemphigus vulgaris and multiple sclerosis1,56
Because Bruton tyrosine kinase is an enzyme expressed on
B lymphocytes and myeloid cells, its irreversible inhibition by
these agents suppresses B cell activation, relevant to IgG4ND; and (4) elotuzumab, a monoclonal anti-SLAMF7 antibody ready to begin1; elotuzumab is a rational therapy for
IgG-4 diseases because targets key cellular interactions between activated B cell subsets, plasmablasts, and CD4+ CTLs
that all express SLAMF7.1
Conclusions on the Clinical Importance of IgG4ND, the Functions of IgG4 as Related to
Immunotherapies, and the Potential Role of
IgG4-Antibody Titers as Disease Biomarkers
The purpose of this article is to increase awareness and
highlight the progress made in our understanding of the
unique function of IgG4-antibodies and their associations
with speciﬁc neurologic diseases which, in contrast to their
IgG1 counterparts, have a more severe clinical phenotype
and distinct response to immunotherapies. Unlike the other
IgG isotypes, the IgG4 antibodies do not activate cellular or
6

complement-mediated immune responses, which are directly targeted by IVIg and conventional immunotherapies,
but they exert pathogenicity by blocking protein-protein
interactions and signal transduction. As a result, IgG4-ND
do not respond to IVIg like their IgG1 counterparts but
respond impressively well to anti–B cell therapies which, if
initiated early in the disease course, may ensure faster recovery preventing long-term disabilities. Importantly, there
is convincing evidence that IgG-4 speciﬁc antibody titers are
reduced in remissions and increased in exacerbations, having
the potential to serve as reliable disease biomarkers not only
in future controlled trials but also in current clinical practice.
Because IgG4 antibody titers seem to correlate with the
clinical status within the same patient,25 it may serve as a
monitoring tool not only in assessing disease activity and
treatment response but also in guiding the need for the next
anti–B cell infusion therapy. In some patients, IgG4 antibody
titers decrease more than 90% or even become negative after
rituximab, as noted in MuSK-MG47 and in some autoimmune nodopathy patients,25 suggesting that antibody reappearance or signiﬁcant titer increase may precede a relapse
and guide the need for retreatment. If proven in controlled
studies that IgG4 antibody titers are a solid biomarker for
long-term therapy, it will be a remarkably novel observation
in autoimmune neurotherapeutics. Currently, in IgG-1
antibody-mediated chronic autoimmune neurologic diseases, antibody titers are not reliable biomarkers, as observed
with anti-MAG and antiganglioside antibodies in neuropathies,53 anti-AChR antibodies in MG, anti-HMGCR or SRP
antibodies in inﬂammatory myopathies, or anti-GAD antibodies in stiﬀ-person syndrome57; even anti-MOG and AQP-4
antibodies, although helpful, are not consistent predictors of
disease relapse.
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673-680.
Jacobs BC, O’Hanlon GM. Bullens RWM et al mmunoglobulins inhibit pathophysiological eﬀects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody binding. Brain. 2003;126(pt 10):2220-2234.
Dalakas MC, Spaeth PJ. The importance of FcRn in Neuro-immunotherapies: from
IgG catabolism, FCGRT gene polymorphisms, IVIg dosing and eﬃciency to speciﬁc
FcRn inhibitors. Ther Adv Neurol Disord. 2021;14:1756286421997381.
Yu Z, Lennon VA. Mechanism of intravenous immune globulin therapy in antibodymediated autoimmune diseases. N Engl J Med. 1999;340(3):227-228.
Li N, Zhao M, Hilario-Vargas J, et al. Complete FcRn dependence for intravenous Ig
therapy in autoimmune skin blistering diseases. J Clin Invest. 2005;115(12):3440-3450.
Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneﬁcial
eﬀect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest. 1994;94(5):1729-1735.
Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous
immunoglobulin infusions as treatment for dermatomyositis. N Engl J Med. 1993;
329(27):1993-2000.
Malik U, Oleksowicz L, Latov N, Cardo LJ. Intravenous y-globulin inhibits binding of
anti-GMI to its target antigen. Ann Neurol. 1996;39(1):136-139.
Tackenberg B, Jelcic I, Baerenwaldt A, et al. Impaired inhibitory Fcgamma receptor
IIB expression on B cells in chronic inﬂammatory demyelinating polyneuropathy. Proc
Natl Acad Sci U S A. 2009;106(12):4788-4792.
Anthony RM, Nimmerjahn F, Ashline DJ, Reinhold VN, Paulson JC, Ravetch JV.
Recapitulation of IVIG anti-inﬂammatory activity with a recombinant IgG Fc. Science.
2008;320(5874):373-376.
Lunneman JD, Nimmerjahn F, Dalakas MC. Intravenous immunoglobulin in neurology: mode of action and clinical eﬃcacy. Nat Rev Neurol. 2015;11(2):80-89.
Quast I, Keller CW, Maurer MA, et al. Sialylation of IgG Fc domain impairs complement dependent cytotoxicity. J Clin Invest. 2015;125(11):4160-4170.
Dalakas MC. B cells as therapeutic targets in autoimmune neurological disorders. Nat
Clin Pract Neurol. 2008;4(10):557-567.
Unger PA, Lighaam LC, Vermeulen E, et al. Divergent chemokine receptor expression and
the consequence for human IgG4 B cell responses. Eur J Immunol. 2020;50(8):1113-1125.
Wallace ZS, Mattoo H, Mahajan VS, et al. Predictors of disease relapse in IgG4-related
disease following rituximab. Rheumatology (Oxford). 2016;55(6):1000-1008.
Hehir MK, Hobson-Webb LD, Benatar M. Rituximab as treatment for anti-MuSK
myasthenia gravis: Multicenter blinded prospective review. Neurology. 2017;89(10):
1069-1077.
Mariapaola Marino M, Basile U, Spagni G, et al. Long-lasting rituximab-induced
reduction of speciﬁc—but not total—IgG4 in MuSK-positive myasthenia gravis. Front
Immunol. 2020;11:613.
Dalakas MC. Progress in the therapy of myasthenia gravis: getting closer to eﬀective
targeted immunotherapies. Curr Opin Neurol. 2020;33(5):545-552.
Gadoth A, Zekeridou A, Klein CJ, et al. Elevated LGI1-IgG CSF index predicts worse
neurological outcome. Ann Clin Transl Neurol. 2018;5(5):646-650.
Majumder S, Mohapatra S, Lennon RJ, et al. Rituximab maintenance therapy reduces
rate of relapse of pancreaticobiliary immunoglobulin G4-related disease. Clin Gastroenterol Hepatol. 2018;16(12):1947-1953.
Dalakas MC. Inhibition of B cell functions: implications for neurology. Neurology.
2008;70(23):2252-2260.
Lebrun C, Bourg V, Bresch S, et al. Therapeutic target of memory B cells depletion
helps to tailor administration frequency of rituximab in myasthenia gravis.
J Neuroimmunol. 2016;298:79-81.
Dalakas MC, Rakocevic G, Salajegheh M, et al. Placebo-controlled trial of rituximab in
IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy. Ann
Neurol. 2009;65(3):286-293.
Cree BAC, BennettJL, KimHJ, et al. Inebilizumab for the treatment of neuromyelitis
optica spectrum disorder(N- MOmentum): a double- blind, randomized placebocontrolled phase 2/3 trial. Lancet. 2019;394(10206):1352-1363.
Alexopoulos H, Biba A, Dalakas MC. Anti–B-Cell therapies in autoimmune neurological diseases: rationale and eﬃcacy trials. Neurotherapeutics. 2016;13(1):20-33.
Reich DS, Arnold DL, Vermersch P, et al Safety and eﬃcacy of tolebrutinib, an oral
brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2021;20(9):
729-738.
Dalakas MC, Fujii M, Li M, et al. High-dose intravenous immunoglobulin for stiﬀperson syndrome. N Engl J Med. 2001;345(26):1870-1876.
Dalakas MC. Update on intravenous immunoglobulin in neurology: modulating
neuro-autoimmunity, evolving factors on eﬃcacy and dosing and challenges on
stopping chronic IVIg therapy. Neurotherapeutics. Accessed November 21, 2021.
https://doi.org/10.1007/s13311-021-01108-4.

Neurology: Neuroimmunology & Neuroinflammation | Volume 9, Number 1 | January 2022

7

IgG4-Mediated Neurologic Autoimmunities: Understanding the Pathogenicity of IgG4,
Ineffectiveness of IVIg, and Long-Lasting Benefits of Anti−B Cell Therapies
Marinos C. Dalakas
Neurol Neuroimmunol Neuroinflamm 2022;9;
DOI 10.1212/NXI.0000000000001116
This information is current as of November 29, 2021
Updated Information &
Services

including high resolution figures, can be found at:
http://nn.neurology.org/content/9/1/e1116.full.html

References

This article cites 57 articles, 5 of which you can access for free at:
http://nn.neurology.org/content/9/1/e1116.full.html##ref-list-1

Subspecialty Collections

This article, along with others on similar topics, appears in the
following collection(s):
Autoimmune diseases
http://nn.neurology.org//cgi/collection/autoimmune_diseases

Permissions & Licensing

Information about reproducing this article in parts (figures,tables) or in
its entirety can be found online at:
http://nn.neurology.org/misc/about.xhtml#permissions

Reprints

Information about ordering reprints can be found online:
http://nn.neurology.org/misc/addir.xhtml#reprintsus

Neurol Neuroimmunol Neuroinflamm is an official journal of the American Academy of Neurology.
Published since April 2014, it is an open-access, online-only, continuous publication journal. Copyright
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American
Academy of Neurology.. All rights reserved. Online ISSN: 2332-7812.

